Vinati Organics VINATIORGA
Specialty chemicals maker and global leader in isobutylbenzene (IBB), the key starting material for ibuprofen
Mapped in 1 theme: Pharmaceuticals.
Where Vinati Organics sits in the supply chain
Vinati Organics appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › KSMs & intermediates
Indirect supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,900 | 2,248 | 2,227 |
| Net profit | 323 | 405 | 444 |
Latest-year revenue ₹2,227 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Dominant global share in IBB, so ibuprofen demand anywhere pulls on Vinati
- Net-cash, high-return specialty chemicals franchise
Risks
- Pharma is an indirect exposure - ATBS and butylphenols drive most earnings
- Chemical-cycle and Chinese pricing pressure; the stock has fallen sharply in the year to Oct 2026
Common questions
What does Vinati Organics do?
Specialty chemicals maker and global leader in isobutylbenzene (IBB), the key starting material for ibuprofen.
Where does Vinati Organics sit in the supply chain?
Vinati Organics (NSE: VINATIORGA) is mapped in 1 supply-chain layer: KSMs & intermediates (Pharmaceuticals).
Who are Vinati Organics' peers?
In the KSMs & intermediates layer of Pharmaceuticals: IOL Chemicals & Pharmaceuticals, Aarti Pharmalabs, Aarti Drugs, Granules India and Aurobindo Pharma.
What is Vinati Organics' market cap and valuation?
As of 30 Oct 2026: market cap ₹10,283 Cr, P/E 25.0x, ROCE 19.8%, ROE 14.9%, dividend yield 0.86%.